2024
Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.
Aung T, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger H, Gerstein M, Rimm D. Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma. Clinical Cancer Research 2024, 30: 3520-3532. PMID: 38837895, PMCID: PMC11326985, DOI: 10.1158/1078-0432.ccr-23-3932.Peer-Reviewed Original ResearchGene signatureResistance to immunotherapyResponse to immunotherapyPrediction of treatment outcomeResistant to treatmentAccurate prediction of treatment outcomePredictive of responseImmunotherapy outcomesMelanoma patientsMelanoma specimensValidation cohortPatient stratificationDiscovery cohortTreatment outcomesImmunotherapyMelanomaTumorPatientsCohortS100BOutcomesGene expression dataGenesCD68+macrophagesExpression data
2018
Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer
Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Laboratory Investigation 2018, 98: 1076-1083. PMID: 29858579, PMCID: PMC6119113, DOI: 10.1038/s41374-018-0064-1.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceParaffin EmbeddingPathology, ClinicalReal-Time Polymerase Chain ReactionReceptor, ErbB-2Receptors, EstrogenReproducibility of ResultsSensitivity and SpecificityTissue FixationConceptsIHC/FISHDCIS cohortRT-qPCRMRNA transcript levelsDuctal carcinoma casesFine needle aspiratesMRNA expression levelsHER2 concordanceER positivityDuctal carcinomaHER2 expressionGeneXpert systemCarcinoma casesInvasive tumorsNeedle biopsyBreast cancerEstrogen receptorClinical ImmunohistochemistryBiopsy areaTumor tissueMRNA expressionTumor areaCohortMRNA levelsMRNA markers
2015
GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORT
Vassilakopoulou M, Won M, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Smart W, Diaz A, Atkins J, Komarnicky L, Schultz C, Howard S, Dicker A, Knisely J. GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORT. Neuro-Oncology 2015, 17: v96-v96. PMCID: PMC4638813, DOI: 10.1093/neuonc/nov215.21.Peer-Reviewed Original Research
2014
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue
Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation 2014, 94: 467-474. PMID: 24535259, PMCID: PMC4030875, DOI: 10.1038/labinvest.2014.7.Peer-Reviewed Original ResearchConceptsCold ischemic timeIschemic timeQuantitative immunofluorescenceLevel of expressionTissue qualityER expression levelsBreast cancer casesExpression levelsFormalin fixationInformative epitopesValidation cohortCancer casesBreast cohortProtein statusGlobal assessmentPatient samplesTissue cohortPreanalytical variablesEpitope expressionCohortIntrinsic controlMeasurement of effectsQuality IndexFFPE tissuesEpitopes
2012
Cytoplasmic Estrogen Receptor in Breast Cancer
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research 2012, 18: 118-126. PMID: 21980134, PMCID: PMC3263348, DOI: 10.1158/1078-0432.ccr-11-1236.Peer-Reviewed Original ResearchConceptsEstrogen receptorCytoplasmic stainingCytoplasmic ERCytoplasmic estrogen receptorSpecific cytoplasmic stainingCell line seriesHuman breast tumorsQuantitative immunofluorescent analysisRoutine clinical valueRetrospective cohortTamoxifen resistanceBreast cancerLower incidencePreclinical modelsClinical valueTissue microarrayPatient controlsBreast tumorsNumber of casesClinical specimensMultiple antibodiesWestern blotAverage incidenceAntibodiesCohortQuantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer
Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Research 2012, 14: r124. PMID: 22971274, PMCID: PMC3962029, DOI: 10.1186/bcr3318.Peer-Reviewed Original ResearchConceptsBreast cancer cohortBreast cancerPoor outcomeTumor cellsCancer cohortPoor disease-specific survivalDisease-specific deathDisease-specific survivalBreast cancer patientsIndependent prognostic markerIndependent breast cancer cohortsNon-invasive tumor cellsInvasive tumor cellsReceptor statusNode statusTumor sizeCancer patientsPrognostic markerSignificant associationCohortCancerIsoform expressionPatientsMetastasisOutcomes
2011
Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells
Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. Journal Of Clinical Oncology 2011, 29: 2978-2984. PMID: 21709197, PMCID: PMC3157961, DOI: 10.1200/jco.2010.32.9706.Peer-Reviewed Original ResearchConceptsER-positive patientsEstrogen receptorQuantitative immunofluorescenceBreast cancerTissue microarrayPositive cellsIndependent retrospective cohortsEstrogen receptor measurementsAssessment of survivalTMA cohortFalse-negative resultsRetrospective cohortER immunoreactivityTest discordancePrognostic outcomesIndependent cohortReceptor measurementsLimitations of immunohistochemistryPatientsDiscrepant casesCohortIHC methodPathologists' judgmentsDiscrepant resultsStandardized assaysStandardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer
Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Rothberg B, Zolota V, Syrigos K, Rimm DL. Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer. American Journal Of Pathology 2011, 179: 580-589. PMID: 21722621, PMCID: PMC3157192, DOI: 10.1016/j.ajpath.2011.04.031.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerPrognostic valueMutation-specific antibodiesLung cancerQuantitative immunofluorescenceEpidermal growth factor receptor (EGFR) protein expressionIndependent NSCLC cohortsPopulation-based cohortEGFR mutation rateReceptor protein expressionTotal proteinFalse-positive casesPrediction of responseWestern blot analysisNSCLC cohortRetrospective cohortReceptor measurementsYale cohortEGFR expressionCohortEGFRAQUA technologyProtein expressionAntibodies
2008
Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation
Emerson JW, Dolled-Filhart M, Harris L, Rimm DL, Tuck DP. Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation. Cancer Informatics 2008, 7: cin.s911. PMID: 19352457, PMCID: PMC2664700, DOI: 10.4137/cin.s911.Peer-Reviewed Original ResearchLymph node statusProtein expression levelsNode statusBreast cancerBaseline clinical modelCohort of patientsLack of tumorTissue microarray studyLarge independent cohortsExpression levelsMultiple imputationPatient survivalTraining cohortTissue biomarkersIndependent cohortClinical modelSelect markersCohortSimilar improvementsBiomarker analysisCancerClinical annotationProtein markersBiomarkersFuture studiesAQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.
Gustavson MD, Molinaro AM, Tedeschi G, Camp RL, Rimm DL. AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Archives Of Pathology & Laboratory Medicine 2008, 132: 1746-52. PMID: 18976010, DOI: 10.5858/132.11.1746.Peer-Reviewed Original ResearchConceptsThymidylate synthase expressionSynthase expressionColorectal carcinomaSignificant associationDisease-specific survivalColon cancer outcomesColon cancer survivalKey prognostic biomarkersRetrospective cohortNodal statusPrognostic valueColorectal cancerCancer outcomesCancer survivalPathologic classificationPrognostic biomarkerLarge cohortSecond cohortAQUA scoreCytoplasmic expressionNuclear expressionCohortHigh nuclearCytoplasmic ratioFirst cohort
2006
Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.Peer-Reviewed Original ResearchConceptsBreast cancerPatient outcomesTissue microarraySubset of patientsBreast cancer patientsTissue microarray platformInternal validation setRoutine pathology laboratoriesCancer patientsEstrogen receptorTissue biomarkersIndependent cohortTumor subtypesPredictive valueAcid-base analysisPathology laboratoryRNA expression studiesCancerTissue sectionsPatientsCohortOutcomesFurther validationObjective quantitative analysisBiomarker discovery
2004
Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma
Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma. Cancer Research 2004, 64: 8773-8777. PMID: 15574790, DOI: 10.1158/0008-5472.can-04-1387.Peer-Reviewed Original ResearchConceptsBcl-2 expressionHigh Bcl-2 expressionTissue microarrayMetastatic specimensResponse rateSmall cohortProgression-free survivalImproved response ratesLarge patient cohortMelanoma patientsClark levelEntire cohortBreslow depthClinical variablesPatient cohortMetastatic melanomaContinuous index scoreBetter outcomesIndex scoreMelanoma specimensCohortMelanomaBcl-2PatientsOutcomesX-TileA New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization
Camp RL, Dolled-Filhart M, Rimm DL. X-TileA New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clinical Cancer Research 2004, 10: 7252-7259. PMID: 15534099, DOI: 10.1158/1078-0432.ccr-04-0713.Peer-Reviewed Original Research
2002
Subjective Differences in Outcome Are Seen as a Function of the Immunohistochemical Method Used on a Colorectal Cancer Tissue Microarray
Chung GG, Kielhorn EP, Rimm DL. Subjective Differences in Outcome Are Seen as a Function of the Immunohistochemical Method Used on a Colorectal Cancer Tissue Microarray. Clinical Colorectal Cancer 2002, 1: 237-242. PMID: 12450422, DOI: 10.3816/ccc.2002.n.005.Peer-Reviewed Original ResearchConceptsTissue microarrayTissue sectionsColorectal cancer tissue microarraySemiquantitative grading systemColorectal cancer specimensCancer tissue microarrayPatient outcomesLarge cohortSubjective assessmentCancer specimensImmunohistochemical methodsGrading systemNuclear stainingPathology literatureProtein expressionTissue samplesCell preparationsExpression levelsBeta-catenin antibodyCurrent standardImmunohistochemistryCohortOutcomesApparent increaseExpression
2001
Diagnosis of “ASCUS” in women over age 50 is less likely to be associated with dysplasia
Flynn K, Rimm D. Diagnosis of “ASCUS” in women over age 50 is less likely to be associated with dysplasia. Diagnostic Cytopathology 2001, 24: 132-136. PMID: 11169895, DOI: 10.1002/1097-0339(200102)24:2<132::aid-dc1026>3.0.co;2-n.Peer-Reviewed Original Research